Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyFDA OKs Olutasidenib (Rezlidhia) for Relapsed/Refractory Acute Myeloid Leukemia with IDH1 Mutation

Data from Study 2102-HEM-101, an open-label, single-arm, multicenter phase 1/2 trial, were used to support the approval. The Abbott RealTime IDH1 Assay was used to identify 147 adults with relapsed or refractory AML who had an IHD1 mutation. Olutasidenib treatment resulted in a 35% complete remission (CR) or complete remission with partial hematologic recovery in patients (CRh).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form